Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan-Reference-Cited by-同舟云学术

Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan

Published:2024-06 Issue:6 Volume:84 Page:661-684
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Lombardi Carlo^ORCID,Comberiati Pasquale^ORCID,Ridolo Erminia^ORCID,Cottini Marcello^ORCID,Yacoub Mona Rita^ORCID,Casagrande Silvia^ORCID,Riccò Matteo^ORCID,Bottazzoli Marco^ORCID,Berti Alvise^ORCID

Funder

Università degli Studi di Trento

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40265-024-02037-0.pdf

Reference146 articles.

1. Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42–53. https://doi.org/10.1016/j.crimmu.2022.03.002.

2. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–9. https://doi.org/10.1093/intimm/dxp102.

3. Massey OW, Suphioglu C. Taking a breather: advances in interleukin 5 inhibition for asthma relief. Int J Mol Sci. 2022;23(19):11166. https://doi.org/10.3390/ijms231911166.

4. Keating GM. Mepolizumab: first global approval. Drugs. 2015;75(18):2163–9. https://doi.org/10.1007/s40265-015-0513-8.

5. Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017;77(7):777–84. https://doi.org/10.1007/s40265-017-0740-2.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causality between various cytokines and asthma: a bidirectional two-sample Mendelian randomization analysis;Frontiers in Medicine;2024-08-08